- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT07393126
Effecten van het gebruik van het testproduct op urineren bij gezonde Japanse volwassenen
Effecten van de Consumptie van Testproduct op Urineren bij Gezonde Japanse Volwassenen: Een Gerandomiseerde, Placebogecontroleerde, Dubbelblinde, Parallelgroep-Vergelijkingsstudie
The goal of this clinical trial is to test in Japanese adults who experience concerns regarding urinary frequency. The main question it aims to answer is:
•Does consumption of Cranberry Phospholipids reduce daytime urinary frequency?
Participants will be given the following tasks:
- Take two tablets daily containing Cranberry Phospholipid for eight weeks.
- Answer the questionnaire on the overactive bladder (OAB)-specific quality of life (QOL).
- Answer the questionnaire on OAB symptoms.
- Answer the questionnaire on urinary frequency during the study period. Researchers will compare Cranberry Phospholipids and placebo groups to see if Cranberry Phospholipids reduces daytime urinary frequency.
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Studietype
Inschrijving (Geschat)
Fase
- Niet toepasbaar
Contacten en locaties
Studiecontact
- Naam: Naoko Suzuki
- Telefoonnummer: +81-3-3818-0610
- E-mail: group_gakujutsu@orthomedico.jp
Studie Contact Back-up
- Naam: Asami Baba, PhD
- Telefoonnummer: +81-3-3818-0610
- E-mail: asami-baba@orthomedico.jp
Studie Locaties
-
-
Tokyo
-
Nerima-ku, Tokyo, Japan, 176-0002
- Werving
- Nerima Medical Association Minami-machi Clinic
-
Contact:
- Naoko Suzuki
- Telefoonnummer: +81-3-3818-0610
- E-mail: group_gakujutsu@orthomedico.jp
-
Contact:
- Asami Baba, PhD
- Telefoonnummer: +81-3-3818-0610
- E-mail: asami-baba@orthomedico.jp
-
Hoofdonderzoeker:
- Masafumi Nagata, MD
-
Shinagawa-Ku, Tokyo, Japan, 141-0022
- Werving
- Medical Corporation Seishinkai, Takara Clinic
-
Contact:
- Naoko Suzuki
- Telefoonnummer: +81-3-3818-0610
- E-mail: group_gakujutsu@orthomedico.jp
-
Contact:
- Asami Baba, PhD
- Telefoonnummer: +81-3-3818-0610
- E-mail: asami-baba@orthomedico.jp
-
Hoofdonderzoeker:
- Tsuyoshi Takara, MD
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Japanese
- Men or women
- Adults
- Healthy individuals
- Individuals with positive urine leukocytes at baseline
- Individuals whose score of urinary urgency of overactive bladder symptom score (OABSS) is less than two or total score of OABSS is less than three at baseline
- Individuals whose "frequent urination during the daytime hours" of "symptom bother" of OAB-q is relatively high at baseline
Exclusion Criteria:
- Individuals undergoing medical treatment or having a medical history of malignant tumor, heart failure, or myocardial infarction
- Individuals carrying a pacemaker or an implantable cardioverter defibrillator
- Individuals undergoing treatment for any of the following chronic diseases: cardiac arrhythmia, liver disease, kidney disease, cerebrovascular disorder, rheumatism, diabetes mellitus, dyslipidemia, hypertension, or any other chronic diseases
- Individuals who use or take "Foods for Specified Health Uses", "Foods with Functional Claims", or other functional food/beverage as part of their daily diet
- Individuals currently regularly taking medications (including herbal medicines) and supplements
- Individuals who are allergic to medicines and/or the test-product-related products in this trial
- Individuals with urinary pain
- Individuals undergoing treatment, have had treatment within two months, or need the treatment for diseases related to urination, e.g. benign prostatic hypertrophy, prostatitis, prostate cancer, overactive bladder, hypoactive bladder, cystitis, interstitial cystitis, bladder cancer, bladder stones, urethritis, urethral stricture, neurological disease, polyuria, and nocturnal polyuria
- Individuals have overactive bladder symptom (individuals who urinate eight times or more per day, and have urinary urgency at least once a week)
- Individuals wake up twice or more to urinate at bedtime
- Individuals are pregnant, breast-feeding, and planning to become pregnant
- Individuals have been enrolled in other clinical trials within the last 28 days before the agreement to participate in this trial or plan to participate another trial during this trial
- Individuals are judged as ineligible to participate in the trial by the physician
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Ander
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Verviervoudigen
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Actieve vergelijker: Cranberry Phospholipids
Take two tablets (containing 120 mg cranberry phospholipids/tablet) |
Take two tablets will be taken once daily |
|
Placebo-vergelijker: Placebo
Take two tablets (containing 0 mg cranberry phospholipids/tablet) |
Take two tablets will be taken once daily |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Measured value for the Overactive Bladder Questionnaire (OAB-q) questionnaire item "frequent urination during the daytime hours" after the 8-week intervention
Tijdsspanne: After the 8-week intervention
|
Using OAB-q, we evaluate OAB-specific quality of life (QOL). The questionnaire have 33 items, including 8 items measuring "symptom bother" and 25 items measuring "impact on QOL," with each item rated on a 6-point scale."Impact on QOL" is scored across four domains: "Coping" (8 items), "Concern" (7 items), "Sleep" (5 items), and "Social Interaction" (5 items). Scores are calculated on a scale of 0 to 100, with higher scores indicating a greater degree of difficulty. On the other hand, the "impact on QOL" indicates that the higher the score, the better the QOL. |
After the 8-week intervention
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Individuals whose the response to the OAB-q questionnaire item "frequent urination during the daytime hours" improved by one or more scale points after the 8-week intervention compared to Baseline
Tijdsspanne: Baseline, and after the 8-week intervention
|
Using OAB-q, we evaluate OAB-specific QOL. The questionnaire have 33 items, including 8 items measuring "symptom bother" and 25 items measuring "impact on QOL," with each item rated on a 6-point scale."Impact on QOL" is scored across four domains: "Coping" (8 items), "Concern" (7 items), "Sleep" (5 items), and "Social Interaction" (5 items). Scores are calculated on a scale of 0 to 100, with higher scores indicating a greater degree of difficulty. On the other hand, the "impact on QOL" indicates that the higher the score, the better the QOL. |
Baseline, and after the 8-week intervention
|
|
The amount of change, and percentage of change from Baseline for the OAB-q questionnaire item "frequent urination during the daytime hours" after the 8-week intervention
Tijdsspanne: Baseline, after the 1-week intervention, the 3-week intervention and the 8-week intervention
|
Using OAB-q, we evaluate OAB-specific QOL. The questionnaire have 33 items, including 8 items measuring "symptom bother" and 25 items measuring "impact on QOL," with each item rated on a 6-point scale."Impact on QOL" is scored across four domains: "Coping" (8 items), "Concern" (7 items), "Sleep" (5 items), and "Social Interaction" (5 items). Scores are calculated on a scale of 0 to 100, with higher scores indicating a greater degree of difficulty. On the other hand, the "impact on QOL" indicates that the higher the score, the better the QOL. |
Baseline, after the 1-week intervention, the 3-week intervention and the 8-week intervention
|
|
The measured values, amount of changes, and percentage of changes from Baseline for all other questionnaire items of the OAB-q, excluding "frequent urination during the daytime hours," after the 8-week intervention
Tijdsspanne: Baseline, after the 1-week intervention, the 3-week intervention and the 8-week intervention
|
Using OAB-q, we evaluate OAB-specific QOL. The questionnaire have 33 items, including 8 items measuring "symptom bother" and 25 items measuring "impact on QOL," with each item rated on a 6-point scale."Impact on QOL" is scored across four domains: "Coping" (8 items), "Concern" (7 items), "Sleep" (5 items), and "Social Interaction" (5 items). Scores are calculated on a scale of 0 to 100, with higher scores indicating a greater degree of difficulty. On the other hand, the "impact on QOL" indicates that the higher the score, the better the QOL. |
Baseline, after the 1-week intervention, the 3-week intervention and the 8-week intervention
|
|
The measured values, and amount of changes and percentage of changes from Period 1 for the average frequency of urination during the daytime, during the nighttime, and all day, as measured during Periods 2 to 9
Tijdsspanne: Period 1 (7 days prior to Baseline), Period 2~9 (periods separated by 7 days from the start of intervention)
|
Participants will maintain a daily diary of their urination frequency during two distinct periods: for 7 days immediately preceding the Baseline, and from the beginning of the intervention until the day before the final examination. |
Period 1 (7 days prior to Baseline), Period 2~9 (periods separated by 7 days from the start of intervention)
|
|
Individuals who experienced adverse events
Tijdsspanne: After the 8-week intervention
|
During the trial period, if a participant exhibits any clinically significant "new manifestation of abnormality" or "aggravation" in his/her physical signs and symptoms, it is considered to be an adverse event. |
After the 8-week intervention
|
|
Individuals whose values of urinalysis and peripheral blood test are outside the reference range after intervention despite within the reference range at Baseline
Tijdsspanne: Baseline, and after the 8-week intervention
|
The ratio of cases which had test items stated in urinalysis and peripheral blood examination within their respective standard ranges before intervention but exceeded the ranges after intervention are calculated, intergroup comparison at each time point is performed using tests for comparing proportions. |
Baseline, and after the 8-week intervention
|
|
Body height
Tijdsspanne: Baseline, and after the 8-week intervention
|
Body height is measured using a height meter. |
Baseline, and after the 8-week intervention
|
|
Body weight
Tijdsspanne: Baseline, and after the 8-week intervention
|
Body weight is measured using a body scale. |
Baseline, and after the 8-week intervention
|
|
Blood pressure
Tijdsspanne: Baseline, and after the 8-week intervention
|
Systolic and diastolic blood pressure are measured using a digital wrist-type sphygmomanometer. |
Baseline, and after the 8-week intervention
|
|
Urinalysis
Tijdsspanne: Baseline, and after the 8-week intervention
|
A urine sample (approximately 10 mL) will be collected from each participant, and the samples will be sent to LSI Medience Corporation for analysis. |
Baseline, and after the 8-week intervention
|
|
Peripheral blood examination
Tijdsspanne: Baseline, and after the 8-week intervention
|
A venous blood sample (approximately 10 mL) will be collected from each participant, and the samples will be sent to LSI Medience Corporation for analysis. |
Baseline, and after the 8-week intervention
|
Medewerkers en onderzoekers
Sponsor
Onderzoekers
- Studie stoel: Tsuyoshi Takara, MD, Medical Corporation Seishinkai, Takara Clinic
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Andere studie-ID-nummers
- 01170-0018-29
- UMIN000060011 (Register-ID: UMIN-CTR)
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Beschrijving IPD-plan
Data sharing will be discussed among the research affiliates after the study is completed.
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .